Historical Valuation
Champions Oncology Inc (CSBR) is now in the Overvalued zone, suggesting that its current forward PS ratio of 1.52 is considered Overvalued compared with the five-year average of 42.09. The fair price of Champions Oncology Inc (CSBR) is between -173.42 to -168.65 according to relative valuation methord. Compared to the current price of 6.79 USD , Champions Oncology Inc is Overvalued By -104.03%.
Relative Value
Fair Zone
-173.42--168.65
Current Price：6.79
-104.03%
Overvalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Champions Oncology Inc (CSBR) has a current Price-to-Book (P/B) ratio of 22.18. Compared to its 3-year average P/B ratio of 66.57 , the current P/B ratio is approximately -66.68% higher. Relative to its 5-year average P/B ratio of 45.48, the current P/B ratio is about -51.24% higher. Champions Oncology Inc (CSBR) has a Forward Free Cash Flow (FCF) yield of approximately 6.10%. Compared to its 3-year average FCF yield of -1.26%, the current FCF yield is approximately -585.11% lower. Relative to its 5-year average FCF yield of -0.60% , the current FCF yield is about -1114.23% lower.
P/B
Median3y
66.57
Median5y
45.48
FCF Yield
Median3y
-1.26
Median5y
-0.60
Competitors Valuation Multiple
AI Analysis for CSBR
The average P/S ratio for CSBR competitors is -172.56, providing a benchmark for relative valuation. Champions Oncology Inc Corp (CSBR.O) exhibits a P/S ratio of 1.52, which is -100.88% above the industry average. Given its robust revenue growth of 11.46%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for CSBR
1Y
3Y
5Y
Market capitalization of CSBR increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CSBR in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is CSBR currently overvalued or undervalued?
Champions Oncology Inc (CSBR) is now in the Overvalued zone, suggesting that its current forward PS ratio of 1.52 is considered Overvalued compared with the five-year average of 42.09. The fair price of Champions Oncology Inc (CSBR) is between -173.42 to -168.65 according to relative valuation methord. Compared to the current price of 6.79 USD , Champions Oncology Inc is Overvalued By -104.03% .
What is Champions Oncology Inc (CSBR) fair value?
CSBR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Champions Oncology Inc (CSBR) is between -173.42 to -168.65 according to relative valuation methord.
How does CSBR's valuation metrics compare to the industry average?
The average P/S ratio for CSBR's competitors is -172.56, providing a benchmark for relative valuation. Champions Oncology Inc Corp (CSBR) exhibits a P/S ratio of 1.52, which is -100.88% above the industry average. Given its robust revenue growth of 11.46%, this premium appears unsustainable.
What is the current P/B ratio for Champions Oncology Inc (CSBR) as of Jan 10 2026?
As of Jan 10 2026, Champions Oncology Inc (CSBR) has a P/B ratio of 22.18. This indicates that the market values CSBR at 22.18 times its book value.
What is the current FCF Yield for Champions Oncology Inc (CSBR) as of Jan 10 2026?
As of Jan 10 2026, Champions Oncology Inc (CSBR) has a FCF Yield of 6.10%. This means that for every dollar of Champions Oncology Inc’s market capitalization, the company generates 6.10 cents in free cash flow.
What is the current Forward P/E ratio for Champions Oncology Inc (CSBR) as of Jan 10 2026?
As of Jan 10 2026, Champions Oncology Inc (CSBR) has a Forward P/E ratio of 133.20. This means the market is willing to pay $133.20 for every dollar of Champions Oncology Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Champions Oncology Inc (CSBR) as of Jan 10 2026?
As of Jan 10 2026, Champions Oncology Inc (CSBR) has a Forward P/S ratio of 1.52. This means the market is valuing CSBR at $1.52 for every dollar of expected revenue over the next 12 months.